Afanat 20mg

About Afanat 20mg

Afanat 20mg is used for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations. Manufactured by Natco Pharma Ltd., this targeted therapy contains Afatinib Dimaleate as its active ingredient, which works by irreversibly blocking signals from EGFR proteins that cause cancer cells to multiply. By inhibiting multiple pathways in the ErbB family of proteins, Afanat helps slow tumor progression in carefully selected lung cancer patients. For those requiring dose adjustments or escalation under oncologist supervision, many patients eventually consider Afanat 30mg (Afatinib Dimaleate), which provides higher-strength dosing options. This medication represents an important option in personalized cancer therapy, particularly for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 substitution mutations.

Dosage & Usage

Take Afanat 20mg exactly as prescribed by your oncologist, typically one tablet orally once daily at least one hour before or two hours after food. Swallow the tablet whole with water on an empty stomach to ensure optimal absorption. Your doctor will determine the appropriate starting dose based on your specific EGFR mutation status, previous treatments, and overall health condition. Do not crush, break, or chew the tablets. If you miss a dose and it is less than 12 hours until your next scheduled dose, skip the missed dose and resume your regular schedule. Never double doses to compensate for a missed tablet. Treatment continues until disease progression or unacceptable toxicity occurs, with regular monitoring through imaging studies and laboratory tests. Dose modifications may be necessary based on tolerability, and your healthcare team will provide specific guidance on managing any treatment-related side effects.

Who Is It For?

Afanat 20mg is safe for adult patients with metastatic non-small cell lung cancer whose tumors test positive for specific EGFR mutations (deletions in exon 19 or exon 21 L858R substitution mutations) as detected through FDA-approved testing. This medication is particularly appropriate for first-line treatment in patients with locally advanced or metastatic disease who have not received prior EGFR tyrosine kinase inhibitor therapy. It is not suitable for patients with severe hepatic impairment, those with a history of severe allergic reactions to afatinib, or individuals unable to tolerate the medication's side effect profile, which may include diarrhea and skin reactions. Patients managing other serious conditions may also be candidates for treatments like Bosuvi 100mg (Bosutinib), another targeted therapy in the life-saving drugs category. Women who are pregnant, planning pregnancy, or breastfeeding should not take Afanat due to potential fetal harm. Your oncologist will assess your EGFR mutation status, performance status, organ function, and previous treatment history before determining if Afanat 20mg is appropriate for your specific clinical situation.

Why Buy From SafeRxPills?

SafeRxPills provides secure access to life-saving medications for patients across Australia, the United Kingdom, the United States, and Canada with complete discretion and professional pharmaceutical care. We understand the critical importance of uninterrupted cancer treatment and ensure authentic Natco Pharma products with proper temperature-controlled shipping that typically arrives within 7-14 business days. Our licensed pharmacy team verifies all prescriptions and provides confidential consultation support to address medication questions and coordination with your oncology team. Every order includes secure packaging that protects patient privacy while maintaining medication integrity during international transit. We accept multiple payment methods and maintain transparent pricing without hidden fees, making essential cancer medications accessible to patients who need them most.